Surufatinib for neuroendocrine tumors
Part of Cancer clinical trials.
This study tests a drug called surufatinib for people with neuroendocrine tumors. It aims to see how safe and effective the treatment is in real-world patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a neuroendocrine tumor (confirmed by biopsy or other lab test).
- You have at least one tumor that can be measured on a scan.
- Your doctor expects you to live at least 12 weeks (about 3 months).
- Your organs and bone marrow are working well enough to receive the treatment.
- You have not taken part in another drug trial in the last 4 weeks, and you have not had other cancers in the last 5 years (except for certain skin cancers or cervical cancer in situ).
- You do not have conditions that make surufatinib unsafe, like active bleeding, uncontrolled high blood pressure, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
This study tests a pill called surufatinib after surgery to see if it can prevent neuroendocrine tumors from coming back. It is for patients with high-risk features like advanced stage or a higher grade of tumor.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
This trial tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. If you have this diagnosis and haven't had prior systemic treatment, you may be eligible.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This study tests a combination of two medications (surufatinib and serplulimab) for advanced solid tumors that have stopped responding to standard treatment and show special neuroendocrine markers. The goal is to see if this combination can shrink tumors and help you live longer.
Hear when a new Neuroendocrine (NE) Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.